DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.

Kazuhiro Inoue, Eiji Kumazawa, Hiroshi Kuga, Hiroshi Susaki, Noriko Masubuchi, Tetsuyo Kajimura, CM-Dextran-Polyalcohol-Camptothecin Conjugate Advances in Experimental Medicine and Biology. ,vol. 519, pp. 145- 153 ,(2004) , 10.1007/0-306-47932-X_9

Y H Hsiang, R Hertzberg, S Hecht, L F Liu, Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. Journal of Biological Chemistry. ,vol. 260, pp. 14873- 14878 ,(1985) , 10.1016/S0021-9258(17)38654-4

Jeffrey G Supko, Rocio Garcia-Carbonero, Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clinical Cancer Research. ,vol. 8, pp. 641- 661 ,(2002)

Hironobu Minami, Yasutsuna Sasaki, Kuniaki Itoh, Kyoji Tamanoi, Hirofumi Fujii, Toshihiro Oguma, Tadahiko Igarashi, Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks. Clinical Cancer Research. ,vol. 7, pp. 3056- 3064 ,(2001)

Sosamma J. Berger, Nathan A. Berger, Alice P. Chen, Jeremy D. Shapiro, Susan G. Arbuck, John Wright, J. Michael Hamilton, Carmen J. Allegra, Jean L. Grem, Chris H. Takimoto, Geraldine Morrison, Nancy Harold, Mary Quinn, Brian P. Monahan, Roger A. Band, Jeff Cottrell, Aida Guemei, Victor Llorens, Hilary Hehman, Abdel Salam Ismail, Donald Flemming, David M. Gosky, Haruyo Hirota, Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. Journal of Clinical Oncology. ,vol. 18, pp. 659- 667 ,(2000) , 10.1200/JCO.2000.18.3.659

Ronald L Drengler, John G Kuhn, Larry J Schaaf, Gladys I Rodriguez, Miguel A Villalona-Calero, Lisa A Hammond, Joseph A Stephenson, Jr, Stephanie Hodges, Maura A Kraynak, Brian A Staton, Gary L Elfring, Paula K Locker, Langdon L Miller, Daniel D Von Hoff, Mace L Rothenberg, Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors Journal of Clinical Oncology. ,vol. 17, pp. 685- 696 ,(1999) , 10.1200/JCO.1999.17.2.685

L J van Warmerdam, W W ten Bokkel Huinink, S Rodenhuis, I Koier, B E Davies, H Rosing, R A Maes, J H Beijnen, Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. Journal of Clinical Oncology. ,vol. 13, pp. 1768- 1776 ,(1995) , 10.1200/JCO.1995.13.7.1768

Nancy Kemeny, David Ilson, David Kelsen, Ellen Hollywood, Gary K. Schwartz, John Coyle, Eileen O’Reilly, Leonard B. Saltz, Sunil Sharma, Sarah Kleban, Robert L. De Jager, Martin P. Ducharme, Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clinical Cancer Research. ,vol. 7, pp. 3963- 3970 ,(2001)

Eric K. Rowinsky, Thomas R. Johnson, Charles E. Geyer, Lisa A. Hammond, S. Gail Eckhardt, Ronald Drengler, Leslie Smetzer, John Coyle, Jinee Rizzo, Garry Schwartz, Anthony Tolcher, Daniel D. Von Hoff, Robert L. De Jager, DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies Journal of Clinical Oncology. ,vol. 18, pp. 3151- 3163 ,(2000) , 10.1200/JCO.2000.18.17.3151

J.P Braybrooke, M Ranson, C Manegold, K Mattson, N Thatcher, P Cheverton, M Sekiguchi, M Suzuki, R Oyama, D.C Talbot, Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer. Lung Cancer. ,vol. 41, pp. 215- 219 ,(2003) , 10.1016/S0169-5002(03)00190-9